Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions

Manuscript Number: 

19-0507R2

Author(s): 
Peter S. Conti, David R. Elmaleh, Martin R. Farlow, Ljiljana Kundakovic, Rudolph E. Tanzi, Ronald G. Tompkins

Disclosures

Peter S. Conti

  • Consulting Fees:
    Compensation for attendance at annul advisory board meetings
    Equity:
    Stock options

David R. Elmaleh

  • Consulting Fees:
    Cash and equity
    Equity:
    shares and options >$50000

Martin R. Farlow

  • Consulting Fees:
    Consulting/Advising/DSMB Boards: Allergan, Avanir, AZTherapies, Biogen MA Inc., Cerecin (formerly Accera), Cognition Therapeutics, Cortexyme, Danone, Eisai Inc., Eli Lilly & Company, Longeveron, Green Valley, Medavante, Merck and Co. Inc., Otsuka Pharmaceutical, Proclara (formerly Neurophage Pharmaceuticals), Neurotrope Biosciences, Regenera, Samumed, Swing Therapeutics, Takeda, vTv Therapeutics, Zhejian Hisun Pharmaceuticals
    Patents/Royalties
    Transgenic mouse model patent that is licensed to Elan.
    Grants
    • Agency: 
      AbbVie, Accera, ADCS Posiphen, Biogen, Eisai, Eli Lilly, Genentech, Novartis, Suven Life Sciences, Ltd., vTv Therapeutics
      Dates: 
      Present

Ljiljana Kundakovic

  • Consulting Fees:
    Consultant for AZTherapies paid for preparing and writing the manuscript

Rudolph E. Tanzi

  • Consulting Fees:
    Chair, Scientific Advisory Board, AZTherapies
    Equity:
    Equity in AZTherapies

Ronald G. Tompkins

  • Consulting Fees:
    I serve on a Scientific Advisory Board for AZ Therapies.
    Equity:
    I hold less than 0.01% of stock and stock options in AZ Therapies.